Xiamen Amoytop Biotech Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Li Sun

Geschäftsführender

CN¥2.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	10.8%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Jun 12

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 04

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Mar 25

Geschäftsführer

Li Sun (58 yo)

no data

Amtszeit

CN¥2,196,500

Vergütung

Mr. Li Sun is Chairman & GM of Xiamen Amoytop Biotech Co., Ltd. He was Director and General Manager of Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Xiamen Amoytop Biotech Co., Ltd., Annual General Meeting, Apr 29, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Xiamen Amoytop Biotech Co., Ltd., Annual General Meeting, Apr 29, 2024

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Xiamen Amoytop Biotech Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 19%

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 19%

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.19 in 2Q 2022)

Investor sentiment deteriorates as stock falls 17%

Xiamen Amoytop Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.14 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.71 (vs CN¥0.45 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.10 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.074 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.06 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.06 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.18 in FY 2019)

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.18 in FY 2019)

New 90-day low: CN¥33.40

New 90-day low: CN¥42.70

New 90-day low: CN¥47.20

New 90-day low - CN¥47.35

Xiamen Amoytop Biotech Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

Geschäftsführer

Amtszeit

Vergütung